NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/22/2023
Back to search
Official data from USPTO
PASSAGE BIO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PASSAGE BIO
ST13
US500000088764198Class
5, 42
Filing
88764198
Registration
7145870
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
08/22/2023
Trademark type
Word
Nice classes
5, 42
Filing date
01/17/2020
Registration date
08/22/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/22/2023
Last transaction
08/22/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/29/2021
First use in commerce
03/29/2021
Drawing code
4
Owner type
03
Owner location
Philadelphia, PA
Examiner
SULLIVAN,JOHN C
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Passage Bio, Inc.
Representatives
Connie L. Ellerbach FENWICK & WEST LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for use in gene therapygenetic medicines and regenerative therapies; pharmaceuticals and medical preparations and substances for genetically based diseases and rare disorders; pharmaceuticals and medical preparations and substances for use in the prevention and treatment of diseases and disorders of the central nervous system; medicines for human purposesfor treating genetically based diseases and disorders; pharmaceutical compositionsviral vectors for use in the delivery of gene therapy; pharmaceutical compositionsviral vectors for use in the delivery of gene therapy for rare monogenic central nervous system diseases; pharmaceutical compositions containing adeno-associated virus (AAV) vectors for a system delivering genes to biological cells for use in the treatment of diseasessicknessesdisorders
Class 42
Pharmaceutical research and development; clinical research in the field of genetic medicinegene therapy and regenerative medicines; testinginspectionresearchdevelopment of pharmaceutical preparations and substances for genetic medicinegene therapy and regenerative medicines; biological information analysisgenetic testing for medical research purposes; scientific research in the fields of medicinegeneticsgenetic medicinesregenerative medicinesgene therapybiologicscentral nervous system diseases; providing medical and scientific research information in the fields of pharmaceuticalsgenetics and clinical trials; medical and scientific researchconducting clinical trials for others; compiling scientific and clinical datain particular patient data and data from clinical studiesfor research purposes in the fields of medicinegeneticsgenetics medicinesregenerative medicinesgene therapybiologicsrare disease
Publications
History of USPTO decisions and trademark events.
41 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/22/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/18/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/17/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/17/2023
IUAF
USE AMENDMENT FILED
07/14/2023
EISU
TEAS STATEMENT OF USE RECEIVED
07/14/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/28/2023
EX5G
SOU EXTENSION 5 GRANTED
01/27/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/26/2023
EXT5
SOU EXTENSION 5 FILED
01/12/2023
EEXT
SOU TEAS EXTENSION RECEIVED
01/12/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/08/2022
EX4G
SOU EXTENSION 4 GRANTED
07/06/2022
EXT4
SOU EXTENSION 4 FILED
07/06/2022
EEXT
SOU TEAS EXTENSION RECEIVED
07/06/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/15/2022
EX3G
SOU EXTENSION 3 GRANTED
01/13/2022
EXT3
SOU EXTENSION 3 FILED
01/13/2022
EEXT
SOU TEAS EXTENSION RECEIVED
01/13/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/08/2021
EX2G
SOU EXTENSION 2 GRANTED
07/06/2021
EXT2
SOU EXTENSION 2 FILED
07/06/2021
EEXT
SOU TEAS EXTENSION RECEIVED
07/06/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/06/2021
EX1G
SOU EXTENSION 1 GRANTED
01/04/2021
EXT1
SOU EXTENSION 1 FILED
01/04/2021
EEXT
SOU TEAS EXTENSION RECEIVED
01/04/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/14/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/19/2020
PUBO
PUBLISHED FOR OPPOSITION
05/19/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/29/2020
ALIE
ASSIGNED TO LIE
04/13/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/06/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
04/06/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/06/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
04/06/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/06/2020
DOCK
ASSIGNED TO EXAMINER
04/06/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/24/2020
NWAP
NEW APPLICATION ENTERED
01/21/2020
Continuous trademark protection
Get notified about every new filing that threatens PASSAGE BIO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.